Estimaciones de analistas de Wall Street para Harmony Biosciences Holdings, Inc. (HRMY): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 8 |
| Mantener | 3 |
| Venta | 2 |
| Venta fuerte | 0 |
| Analistas totales | 13 |
| Calificación media (1-5) | 0.46 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $1.11 | ||
| 2026-08-04 | $1.28 | $0.96 | +33.9% |
| 2026-05-07 | $0.55 | $0.76 | -27.6% |
| 2026-02-24 | $0.38 | $0.84 | -54.8% |
| 2025-11-04 | $0.87 | $0.92 | -5.4% |
| 2025-08-05 | $0.68 | $0.78 | -12.8% |
| 2025-05-06 | $0.78 | $0.59 | +32.2% |
| 2025-02-25 | $0.85 | $0.74 | +14.9% |
Ratios de valoración
| Ratio P/E | 13.49 |
| Precio / Valor contable | 2.45 |
| EV / EBITDA | 7.27 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | $6.0M | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Coste de Ventas | $184000 | $1.6M | $27.7M | $55.5M | $83.5M | $121.2M | $156.8M | $198.3M |
| Beneficio Bruto | -$184000 | $4.4M | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| I+D | $12.4M | $69.6M | $19.4M | $30.4M | $70.9M | $76.1M | $145.8M | $189.6M |
| Generales y Administrativos | $29.1M | $80.7M | $95.6M | $132.0M | $163.3M | $192.7M | $221.3M | $272.0M |
| Gastos Operativos | $41.4M | $150.3M | $115.0M | $162.4M | $234.2M | $268.8M | $367.1M | $461.6M |
| Beneficio Operativo | -$41.4M | -$145.9M | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| EBITDA | -$41.3M | -$142.7M | $1.5M | $80.5M | $146.9M | $221.5M | $233.4M | $255.0M |
| Gastos por Intereses | 0 | $6.1M | $28.2M | $24.2M | $18.8M | $23.8M | $17.5M | $14.6M |
| Beneficio Antes de Impuestos | -$39.9M | -$152.0M | -$36.9M | $37.4M | $104.7M | $173.4M | $191.8M | $215.1M |
| Impuestos | 0 | 0 | 0 | $2.8M | -$76.8M | $44.5M | $46.3M | $56.4M |
| Beneficio Neto | -$39.9M | -$152.0M | -$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| BPA | $-1.42 | $-2.94 | $-1.12 | $0.60 | $3.07 | $2.17 | $2.56 | $2.76 |
| BPA Diluido | $-1.42 | $-2.94 | $-1.10 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |
| Acciones en Circulación (Diluidas) | $49.2M | $63.7M | $57.8M | $59.2M | $61.1M | $60.4M | $57.9M | $58.5M |
Precio
| Precio | $42.21 |
| Capitalización | $2.4B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABCL · AUPH · BHVN · CLDX · IMCR · JANX · MNKD
Explorar sector: Healthcare · Biotechnology
Más secciones de HRMY: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones